Home » Authors » Brady Huggett

Articles by Brady Huggett

Avant Dropping TP10 Following Phase II Failure; Stock Tumbles

Feb. 21, 2002

By Brady Huggett

Vela Raises $25M In Series D To Fund Trials, Add Employees

Feb. 20, 2002

By Brady Huggett

Vela Raises $25M In Series D To Fund Trials, Add Employees

Feb. 20, 2002

By Brady Huggett

Amylin Raises $84M Publicly To Fund AC2993 Phase III Trials

Feb. 13, 2002

By Brady Huggett

Amylin Raises $84M Publicly To Fund AC2993 Phase III Trials

Feb. 13, 2002

By Brady Huggett

Deltagen Paying $23.5M For BMS Unit, Adding Discovery Capability

Feb. 12, 2002

By Brady Huggett

Deltagen Paying $23.5M For BMS Unit, Adding Discovery Capability

Feb. 12, 2002

By Brady Huggett

Immunex, Genesis Form Pact To Research, Develop Molecules

Feb. 8, 2002

By Brady Huggett

Immunex, Genesis Form Pact To Research, Develop Molecules

Feb. 8, 2002

By Brady Huggett

ZymoGenetics Raises $120M In Year’s First Biotech IPO

Feb. 4, 2002

By Brady Huggett

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 29, 2026.
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
Boehringer Ingelheim identifies new mGlu3 receptor agonists
BioWorld Science
Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...
GT-02897 exerts efficacy in preclinical multiple myeloma
BioWorld Science
Investigators from the Karl Landsteiner University aimed to evaluate the therapeutic potential of a novel CDK9 inhibitor/degrader, GT-02897, for the potential...